AU2003231231A1 - Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders - Google Patents

Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders

Info

Publication number
AU2003231231A1
AU2003231231A1 AU2003231231A AU2003231231A AU2003231231A1 AU 2003231231 A1 AU2003231231 A1 AU 2003231231A1 AU 2003231231 A AU2003231231 A AU 2003231231A AU 2003231231 A AU2003231231 A AU 2003231231A AU 2003231231 A1 AU2003231231 A1 AU 2003231231A1
Authority
AU
Australia
Prior art keywords
proliferative disorders
pyrimidine derivatives
derivatives useful
amino pyrimidine
treating hyper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003231231A
Inventor
Jianqing Chen
Yuanwei Chen
Barry Hart
Donglei Liu
Sharad K. Verma
Jill E. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2003231231A1 publication Critical patent/AU2003231231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AU2003231231A 2002-05-06 2003-05-02 Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders Abandoned AU2003231231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37832902P 2002-05-06 2002-05-06
US60/378,329 2002-05-06
PCT/US2003/013604 WO2003095448A1 (en) 2002-05-06 2003-05-02 Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders

Publications (1)

Publication Number Publication Date
AU2003231231A1 true AU2003231231A1 (en) 2003-11-11

Family

ID=29420382

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003231231A Abandoned AU2003231231A1 (en) 2002-05-06 2003-05-02 Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2003299474A Abandoned AU2003299474A1 (en) 2002-05-06 2003-05-06 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003299474A Abandoned AU2003299474A1 (en) 2002-05-06 2003-05-06 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders

Country Status (2)

Country Link
AU (2) AU2003231231A1 (en)
WO (2) WO2003095448A1 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
IL166241A (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DK1625121T3 (en) 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4886511B2 (en) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
TWI378923B (en) * 2003-08-15 2012-12-11 Novartis Ag Pyrimidine derivatives
EP1751142A1 (en) 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006004776A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2580838A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2380550T3 (en) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidinediamine compounds and their uses
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR100602320B1 (en) * 2005-05-03 2006-07-18 주식회사 하이닉스반도체 Non-volatile memory device having uniform programming speed
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007111720A2 (en) 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
RS20080272A (en) 2005-12-21 2009-07-15 Pfizer Products Inc., Pyramidine derivatives for the treatment of abnormal cell growth
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
ES2622493T3 (en) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
WO2007105023A1 (en) * 2006-03-15 2007-09-20 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
GB2451594A (en) * 2006-03-15 2009-02-04 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
US8193197B2 (en) 2006-10-19 2012-06-05 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CL2007003049A1 (en) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug COMPOUNDS DERIVED FROM 2,4-DIAMINOPIRIMIDINE; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT PROLIFERATIVE DISORDERS.
EP2537830A1 (en) 2006-12-08 2012-12-26 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1939185A1 (en) * 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer
MX2009006454A (en) 2006-12-22 2009-06-26 Hoffmann La Roche Spiro-piperidine derivatives.
FR2911137B1 (en) * 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2,4-DIANILINOPYRIMIDE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS INHIBITORS OF IKK
JP2010520222A (en) * 2007-03-01 2010-06-10 スーパージェン， インコーポレイテッド Use of pyrimidine-2,4-diamine derivatives and pyrimidine-2,4-diamine derivatives as JAK2 kinase inhibitors
EP1969929A1 (en) 2007-03-12 2008-09-17 Bayer CropScience AG Substituted phenylamidines and their use as fungicides
AU2014201847B2 (en) * 2007-04-18 2015-12-24 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
AU2016201820B2 (en) * 2007-04-18 2018-03-08 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
CA2684447C (en) 2007-04-18 2012-01-24 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
RU2010132728A (en) 2008-01-11 2012-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) BETA AMYLOID MODULATORS
RU2010137300A (en) * 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) BETA AMYLOID MODULATORS
VN29259A1 (en) 2008-04-16 2012-04-25 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102066338A (en) 2008-04-22 2011-05-18 波托拉医药品公司 Inhibitors of protein kinases
MX2010012703A (en) 2008-05-21 2010-12-21 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DE102008049323A1 (en) * 2008-09-29 2010-04-01 Henkel Ag & Co. Kgaa New developer components
KR101324414B1 (en) 2008-10-09 2013-11-01 에프. 호프만-라 로슈 아게 Modulators for amyloid beta
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
ES2555982T3 (en) * 2009-01-15 2016-01-12 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
WO2012061415A1 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
KR101884010B1 (en) 2011-05-04 2018-07-31 어리어드 파마슈티칼스, 인코포레이티드 Compounds for inhibiting cell proliferation in egfr-driven cancers
PT3409278T (en) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Heterocyclic protein kinase inhibitors
JP6106685B2 (en) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
IN2014CN04065A (en) 2011-11-23 2015-09-04 Portola Pharm Inc
EP2606884A1 (en) * 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
KR101446742B1 (en) * 2012-08-10 2014-10-01 한국화학연구원 N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR102334260B1 (en) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 and alk2 inhibitors and methods for their use
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016022460A1 (en) 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
EP3630291B1 (en) 2017-05-26 2024-01-10 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
JP2020525525A (en) 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． RHO-related protein kinase inhibitor, pharmaceutical composition containing RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition
JP7039802B2 (en) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Pharmaceutical composition containing RHO-related protein kinase inhibitor, RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition.
CN111217797B (en) 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing same, and preparation method and application thereof
CN109776522B (en) * 2017-10-30 2020-12-29 广东东阳光药业有限公司 Substituted heteroaryl compounds, compositions and uses thereof
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
JP2021521170A (en) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド PIM kinase inhibitors for the treatment of myeloproliferative neoplasms and cancer-related fibrosis
WO2020006724A1 (en) * 2018-07-05 2020-01-09 清华大学 Compound for targeted degradation of fak protein and use thereof
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
CN111362922A (en) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2, 4-diaminopyrimidine derivatives and their use
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN114105887B (en) * 2021-09-16 2023-12-01 沈阳药科大学 Aminopyrimidine derivative and preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003031406A2 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
DK1438053T3 (en) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidine derivatives, drug containing these compounds, their use and methods for their preparation

Also Published As

Publication number Publication date
WO2004046118A2 (en) 2004-06-03
WO2004046118A3 (en) 2004-08-12
WO2003095448A1 (en) 2003-11-20
AU2003299474A8 (en) 2004-06-15
AU2003299474A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
AU2003231231A1 (en) Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
EP1511730B8 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
SI1487805T1 (en) Pyrimidine derivatives
AU2003216660A1 (en) N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AU2003275632A1 (en) N-oxide compounds
PL372756A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003274025A1 (en) Pyridine derivatives useful as herbicides
AU2003216290A1 (en) Secure online purchasing
AU2003219410A1 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003210597A1 (en) Methods for treating eye disorders
AU2002339185A1 (en) Pyridine and pyrimidine derivatives
AU2003216677A1 (en) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AU2002362806A1 (en) Pyrimidine derivatives
AU2003272886A1 (en) (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
AU2003260984A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2003244181A1 (en) Phenoxypyridine derivative or salt thereof
AU2003261756A1 (en) Acrylamide derivatives
AU2003264252A1 (en) Pyridine-substituted pyrazolopyridine derivative
AU2003223475A1 (en) Substituted pyrazine derivatives
AU2003231459A1 (en) Pyrimidine derivative
AU2002368112A1 (en) Pyrimidine derivatives
AU2003292435A1 (en) 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 494 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME CHEN, Y.; HART, B.; WOOD, J.; CHEN, J. AND BAYER PHARMACEUTICALS CORPORATION, APPLICATION NO. 2003231231, UNDER INID(43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003